Analgesic Efficacy of an Oral Transmucosal Spray Formulation of Meloxicam, Alone or in Combination with Tramadol in Cats with Naturally Occurring Osteoarthritis
World Small Animal Veterinary Association World Congress Proceedings, 2015
B.P. Monteiro1; M.P. Klinck1; M. Moreau1; M. Guillot1; P.V.M. Steagall2; J.P. Pelletier3; J. Martel-Pelletier3; D. Gauvin1; E. Troncy1
1GREPAQ (Animal Pharmacology Research Group of Québec), University of Montréal, Saint-Hyacinthe, Canada; 2Sciences Cliniques, University of Montréal, Saint-Hyacinthe, Canada; 3Osteoarthritis Research Unit University of Montréal Hospital Centre, University of Montréal, Montréal, Canada

This study aimed to evaluate the analgesic efficacy of meloxicam spray alone or in combination with tramadol in cats with naturally occurring osteoarthritis.

Fifteen geriatric cats were included in a prospective randomised blinded study after approval by the local ethics committee. For 25 days, cats were orally administered placebo BID + meloxicam spray (~ 0.05 mg/kg SID) (MG: meloxicam group; n = 7), or tramadol (3 mg/kg BID) + meloxicam spray (TMG: tramadol-meloxicam group; n = 8). Evaluations performed at baseline (D0) and week 3 (W3) consisted of: 1) peak vertical force (PVF); 2) night-time motor activity (MA); 3) paw withdrawal threshold (PWT) with electronic von Frey; 4) response to mechanical temporal summation (RMTS). Data were analysed with a mixed model method and Fisher's exact test.

From D0 to W3: 1) PVF (% of body weight) increased significantly (p = 0.02) in both groups (no difference between groups); 2) MA increased in the MG (p = 0.02) but not in the TMG; 3) PWT (grams) was not different between groups or within time in both groups; 4) RMTS (number of stimuli) was not different in both groups. A large portion (5/7) reached the cut-off value in TMG, versus 1/7 in MG (p = 0.05). Gastrointestinal adverse-effects were self-limiting in 6 cats; 5/6 from TMG.

Treatment with meloxicam spray demonstrated similar effects based on PVF, MA, and PWT as has been previously observed with oral meloxicam in osteoarthritic cats (Guillot et al. 2013). The tramadol-meloxicam combination provided no evident benefit.

  

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

B.P. Monteiro
GREPAQ (Animal Pharmacology Research Group of Québec)
University of Montréal
Saint-Hyacinthe, Canada


MAIN : Pain Management : Efficacy of Spray Formulation of Meloxicam
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27